Cardinal Health(US:CAH) Jing Ji Guan Cha Wang·2026-02-13 14:36Core Viewpoint - Cardina Health (CAH.US) reported revenue growth in its recent earnings report, leading to an increase in stock price and several institutions raising their target prices [1] Group 1: Earnings Performance - For the second quarter of fiscal year 2026, the company reported revenue of $65.627 billion, a year-over-year increase of 18.75% [2] - Net profit reached $467 million, reflecting a 16.75% year-over-year growth, primarily driven by the pharmaceutical distribution business [2] - Following the earnings release, the stock price experienced a fluctuation of 6.91% over the week, peaking at $230.81 on February 6 and dipping to $212.03 on February 5 [2] Group 2: Institutional Opinions - TD Cowen maintained a "Buy" rating on February 11, 2026, raising the target price from $233 to $251 based on better-than-expected earnings and industry outlook [3] - Among 20 institutions that provided insights in February, 80% rated the stock as "Buy" or "Hold," with an average target price of $251.13 [3] - The overall healthcare sales sector saw a rise of 1.05% during the same period [3] Group 3: Market Activity - On the earnings release date (February 5), trading volume reached 3.58 million shares, but decreased to 126,800 shares by February 11, indicating a drop in trading activity [4] - Prior to the earnings report, from November to December 2025, the company experienced several days of significant trading volume increases, such as a 12.24% surge on November 24 [4]